Verapamil hydrochloride injection labels and packages: Difference between revisions

Revision as of 00:02, 5 March 2014

Verapamil
CALAN tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CALAN SR tablet extended release^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
VERAPAMIL HYDROCHLORIDE injection^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Verapamil
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Principal Display Panel

Verapamil Hydrochloride Injection, USP

10 mg (2.5 mg/mL)

1 x 4 mL Single-Dose Fliptop Vial

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AE}} {{AK}}
+'''Principal Display Panel'''
+Verapamil Hydrochloride Injection, USP
+mg (2.5 mg/mL)
+x 4 mL Single-Dose Fliptop Vial
+{|
+|[[image:verainj4.jpg|500px|thumb]]
+|}